as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 29 Sep 2026
₹1,924.1
Change
-10.9 (-0.56%)
Open
₹1,952.9
Prev. Close
₹1,935.0
Day High
₹1,990.0
Day Low
₹1,905.0
Volume Analysis
Traded
21,732
Delivered
9,445
Delivery %
43.46%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹2,059.4 | ₹2,024.7 | ₹1,974.4 | ₹1,939.7 | ₹1,889.4 | ₹1,854.7 | ₹1,804.4 |
| Fibonacci | ₹2,024.7 | ₹1,992.23 | ₹1,972.17 | ₹1,939.7 | ₹1,907.23 | ₹1,887.17 | ₹1,854.7 |
| Camarilla | ₹1,947.48 | ₹1,939.68 | ₹1,931.89 | ₹1,939.7 | ₹1,916.31 | ₹1,908.52 | ₹1,900.73 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-5.1%
1 Month
+23.78%
3 Months
+32.37%
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Company Overview
Sector
Healthcare
Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.
TopFund Analysis
Novartis India Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 55/100. The strongest factor is Corporate Governance (85/100), while Liquidity (31/100) is the weakest area to weigh before deciding.
TopFund Score — Fundamentals Quality
55/100 — AverageData confidence: 60/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 29 Sep 2026 · How we calculate this →
Corporate Governance
Institutional Ownership
Risk & Volatility
Liquidity
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
The Officials of the Company will be participating in the Conference / Meeting scheduled on Emerging India CEO Forum by Nuvama on Monday, September 28, …
Source: BSE regulatory filings, via Screener.in.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 28.6% | 28.61% | 28.6% | 28.61% | 28.6% | 28.61% | 28.6% | 28.61% | 28.5% | 28.6% | 27.81% | 27.79% |
| Promoters | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% |
| FII | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.17% | 0.16% | 0.15% |
| DII | 0.52% | 0.52% | 0.52% | 0.52% | 0.53% | 0.53% | 0.53% | 0.53% | 0.63% | 0.53% | 1.35% | 1.39% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Novartis India Limited (this stock) | — | — | — | — |
| Sun Pharmaceutical Ind L | 444,405 | 35.2 | 5.32 | 16.0% |
| Divi S Laboratories Ltd | 253,694 | 85.2 | 15.14 | 16.5% |
| Torrent Pharmaceuticals L | 189,746 | 85.0 | 20.11 | 27.4% |
| Apollo Hospitals Enter. L | 128,055 | 60.9 | 13.51 | 21.2% |
| Zydus Lifesciences Ltd | 120,089 | 24.7 | 4.48 | 21.2% |
| Cipla Ltd | 111,985 | 31.3 | 3.25 | 11.6% |
Which Mutual Funds Hold Novartis India Limited?
Frequently Asked Questions about Novartis India Limited
Novartis India Limited (NOVARTIND) closed at ₹1,924.1 on NSE on 29 September 2026, down 10.9 (0.56%) from the previous close.
Novartis India Limited trades on the NSE (National Stock Exchange of India) under the symbol NOVARTIND.
Novartis India Limited has a TopFund Quality Score of 55/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Novartis India Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.